Poster

Results from COG0201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild-to-Moderate Alzheimer’s Disease

Vijverberg EGB, Catalano S, Hamby ME, et al. Results from COG0201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild-to-Moderate Alzheimer’s Disease. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.

Results from COG0201: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild-to-Moderate Alzheimer’s Disease Read More »

Differentiated retinal pigment epithelial cells as a model for uncovering sigma-2 receptor functions and novel therapeutics for dry AMD

Reaver A, Lizama BN, Caggiano AO, Hamby ME. Differentiated retinal pigment epithelial cells as a model for uncovering sigma-2 receptor functions and novel therapeutics for dry AMD. Poster presented at 2024 Association for Research in Vision & Ophthalmology.

Differentiated retinal pigment epithelial cells as a model for uncovering sigma-2 receptor functions and novel therapeutics for dry AMD Read More »

Identification of New Pharmacodynamic Biomarkers of CT1812 that Correlate with Favorable Functional Connectivity of the Brain

Di Caro V, Pandey K, Cho E, et al. Identification of New Pharmacodynamic Biomarkers of CT1812 that Correlate with Favorable Functional Connectivity of the Brain. e-Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.

Identification of New Pharmacodynamic Biomarkers of CT1812 that Correlate with Favorable Functional Connectivity of the Brain Read More »

Proteomic Analysis from Alzheimer’s Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812

Lizama B, Duong D, Pandey K, et al. Plasma Proteomic Analysis from Alzheimer’s Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812. Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.

Proteomic Analysis from Alzheimer’s Patients in SPARC Clinical Trial to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812 Read More »

Analysis of CSF Samples from a Phase 2 Clinical Trial in Alzheimer’s Patients Show that CT1812 can Modulate α-synuclein

Di Caro V, Pandey K, Duong D, et al. Analysis of CSF Samples from a Phase 2 Clinical Trial in Alzheimer’s Patients Show that CT1812 can Modulate α-synuclein. Poster presented at: AD/PD™ 2024 Alzheimer’s & Parkinson’s Diseases Conference; Lisbon, Portugal.

Analysis of CSF Samples from a Phase 2 Clinical Trial in Alzheimer’s Patients Show that CT1812 can Modulate α-synuclein Read More »

A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease

Caldwell J, Cho E, Knezovich N, et al. A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease. Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting; Washington DC.

A transcriptomic analysis to investigate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease Read More »

A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease

Cho E, Caldwell J, Pandey K, et al. A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease. Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting; Washington DC.

A proteomic analysis to elucidate the role of sigma-2 receptor modulators CT1812 and CT2168 in a mouse model of Alzheimer’s disease Read More »

Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease

Reaver AJ, Lizama BN, Pandey K, et al. Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease. Poster presented Nov 2023 at: Society for Neuroscience (SfN) annual meeting; Washington DC.

Exploratory omics study reveals potential roles of sigma-2 receptor modulators in AAV1/2A53T-aSyn rat model of Parkinson’s disease Read More »

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.brightfocus.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.preventblindness.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to https://lewybodyresourcecenter.org/

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.lbda.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.alz.org